ACIN

37.7502.22%

Weekly Recap | AstraZeneca -1.06%, most brokers rate it buy

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

AstraZeneca (AZN) slipped 1.06% this week to close at $184.45, while the S&P 500 rose 2.51%, leaving the stock about 3.57 percentage points behind the index. Price action skewed weak: Monday opened at $189.36 and stalled near $190.165, then Friday (13 Nov) closed at $184.45, with the week’s low of $183.53 set on Wednesday (11 Nov). Average daily volume of around 1.84m shares was roughly 37% below the 60-day median, pointing to thinner participation.

Key Events

The week’s headlines centred on pipeline and commercial moves. On 10 Nov, AstraZeneca acquired bacterial vaccine biotech Omniose after a three-year research collaboration. The same day, the company awarded $1.6m to programmes improving healthcare access across the US. On 11 Nov, reports surfaced that AstraZeneca had made a $10bn bid for Rhythm Pharma, raising attention on its obesity pipeline. On 13 Nov, Baxfendy won EU panel backing for hypertension treatment. The following day, the FDA approved the IMFINZI bladder cancer regimen, and the positive EU opinion on Baxfendy lifted shares nearly 4% in after-hours trading. Meanwhile, Bloomberg News reported AstraZeneca was cutting 600 sales jobs in the US.

Analyst Ratings

Twelve firms cover AstraZeneca: 7 rate it buy, 2 rate it overweight, 2 rate it hold, and 1 rates it sell. The consensus rating is buy, with a consensus target of $208.075, about 12.8% above the latest close of $184.45. The target range of $158 to $240 shows wide dispersion. Within the pharmaceutical industry, AstraZeneca ranks 23rd out of 208 companies on analyst rating.

The Week Ahead

US macro data dominates the coming week, with the New York Fed manufacturing index on 16 Nov and retail sales, import prices and industrial production on 17 Nov. On the stock itself, AstraZeneca’s Q4 FY2026 earnings are scheduled for pre-market on 9 Feb 2027, when attention will turn to the commercial progress of its obesity and oncology pipelines.

In Short

This week AstraZeneca diverged from the broader market, falling slightly while the S&P 500 climbed, and trading volume narrowed. The latest session’s flow showed large-lot money as a net buyer, while retail flow was roughly balanced. Broker coverage tilts towards buy, with the consensus target about 12.8% above spot, though the gap of more than $80 between high and low targets signals real disagreement. The tension to watch: a dense run of pipeline approvals alongside job cuts, while macro retail data will add context on the consumer side.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.